Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO

Kyle Blankenship

As part of CEO Paul Hudson’s mission to revamp the company’s strategy around oncology and immunology R&D, Sanofi unwrapped plans in February to hive off …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Forbion raises €2.1B for two new biotech funds after series of company exits

Exclusive: Biotech tools company raises $75M for protein manufacturing tech

Maryland biotech gets green light for stem cell-derived therapy for diabetes, aiming to compete with Vertex

Tolerance Bio emerges from stealth with $17.2M to advance therapies developed from the thymus

Eli Lilly reveals £279M investment in the UK through new government deal

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Sanofi has a name for its ingredients spinoff, taps Centrient head Karl Rotthier as first CEO